Clinical Trial Detail

NCT ID NCT01468896
Title Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

head and neck squamous cell carcinoma

Therapies

Cetuximab

Age Groups: adult

No variant requirements are available.